Search Results
PSMA Scans & Pluvicto (lutetium-177) in 2022 | Geoffrey Johnson, MD, PhD | PCRI Conference 2022
New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRI
PSMA & Lutetium-177 in 2022 | Eugene Kwon, MD | DIY Combat Manual for Beating Prostate Cancer Part 4
Lu-PSMA Radioligand Therapy
ECLIPSE - A Randomized Phase 3 Trial for 177-Lu-PSMA-I&T in patients with mCRPC
Day 2 | Advanced Treatments, LU-177, Extended Q+A | 2022 Prostate Cancer Patient Conference
Prostate Cancer Clinical Trials With Pluvicto
What is Pluvicto?
Staging Prostate Cancer, PSA Screening, and What If You Have a High PSA? | Mark Scholz, MD | PCRI
177 Lu PSMA Treatment for Prostate Cancer (Update: FDA approved on 3/23/22)
PSMA-PET scanning and management of cN1 prostate cancer
Fernando Acosta's Testimonial with Lutetium-177 PSMA Radioligand Therapy.
